Changeflow GovPing Pharma & Drug Safety Chimeric Transposases and Fusion Proteins Paten...
Routine Notice Added Final

Chimeric Transposases and Fusion Proteins Patent Application

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085332A1) detailing chimeric transposases and fusion proteins. The application, filed on October 3, 2025, by inventors Joseph S. Lucas, Blair B. Madison, and Olga Batalov, covers polynucleotides, vectors, and methods for modifying cells using these proteins.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a patent application filed with the USPTO, specifically application number US20260085332A1, titled 'Chimeric Transposases and Fusion Proteins'. It describes novel chimeric transposases and fusion proteins, along with polynucleotides encoding them, vectors, and methods for their use in modifying cells. The application was filed on October 3, 2025, by inventors Joseph S. Lucas, Blair B. Madison, and Olga Batalov.

As a patent application, this document does not impose direct regulatory obligations or compliance deadlines on entities. However, it represents potential future intellectual property that could impact research and development in the biotechnology and pharmaceutical sectors. Companies involved in gene editing, protein engineering, or related therapeutic development should be aware of this filing for competitive intelligence and potential licensing considerations.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

CHIMERIC TRANSPOSASES AND USES THEREOF

Application US20260085332A1 Kind: A1 Mar 26, 2026

Inventors

Joseph S. LUCAS, Blair B. MADISON, Olga BATALOV

Abstract

Provided herein are chimeric transposases and chimeric site-specific fusion proteins, polynucleotides encoding the chimeric transposases and chimeric site-specific fusion proteins, and vectors and transposons comprising the polynucleotides. Also provided are methods of making the chimeric transposases and chimeric fusion proteins, cells that are modified using the chimeric transposases or chimeric site-specific fusion proteins provided herein and methods using such cells.

CPC Classifications

C12N 15/907 C12N 9/22 C12N 2800/90

Filing Date

2025-10-03

Application No.

19349664

View original document →

Named provisions

Inventors Abstract CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
October 3rd, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085332A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Gene Editing Protein Engineering
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!